DK0766512T3 - Replikationskompetent herpes simplex-virus formidler destruktion af neoplastiske celler - Google Patents

Replikationskompetent herpes simplex-virus formidler destruktion af neoplastiske celler

Info

Publication number
DK0766512T3
DK0766512T3 DK95924631T DK95924631T DK0766512T3 DK 0766512 T3 DK0766512 T3 DK 0766512T3 DK 95924631 T DK95924631 T DK 95924631T DK 95924631 T DK95924631 T DK 95924631T DK 0766512 T3 DK0766512 T3 DK 0766512T3
Authority
DK
Denmark
Prior art keywords
herpes simplex
simplex virus
replication competent
competent herpes
neoplastic cells
Prior art date
Application number
DK95924631T
Other languages
Danish (da)
English (en)
Inventor
Toshihiro Mineta
Robert L Martuza
Samuel D Rabkin
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of DK0766512T3 publication Critical patent/DK0766512T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/30—Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK95924631T 1994-06-23 1995-06-23 Replikationskompetent herpes simplex-virus formidler destruktion af neoplastiske celler DK0766512T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/264,581 US5585096A (en) 1994-06-23 1994-06-23 Replication-competent herpes simplex virus mediates destruction of neoplastic cells
PCT/US1995/007858 WO1996000007A1 (fr) 1994-06-23 1995-06-23 Destruction de cellules neoplasiques operee par le virus de l'herpes simplex a competition de replication

Publications (1)

Publication Number Publication Date
DK0766512T3 true DK0766512T3 (da) 2009-02-09

Family

ID=23006703

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95924631T DK0766512T3 (da) 1994-06-23 1995-06-23 Replikationskompetent herpes simplex-virus formidler destruktion af neoplastiske celler

Country Status (9)

Country Link
US (1) US5585096A (fr)
EP (2) EP0766512B1 (fr)
JP (1) JP3726841B2 (fr)
AT (2) ATE409751T1 (fr)
AU (2) AU679644B2 (fr)
CA (1) CA2193491C (fr)
DE (2) DE69535851D1 (fr)
DK (1) DK0766512T3 (fr)
WO (1) WO1996000007A1 (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770274B1 (en) * 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
CA2051289C (fr) * 1990-09-14 2002-11-26 Robert L. Martuza Destruction de cellules neoplasiques a l'aide d'un virus
JP3974167B2 (ja) 1992-03-31 2007-09-12 アーチ デベロプメント コーポレイション 遺伝子，腫瘍及びウイルス感染の治療，並びにプログラムされた細胞死（アポプトーシス）を予防するための方法及び組成物
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US6699468B1 (en) * 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
ATE324435T1 (de) * 1995-02-21 2006-05-15 Cantab Pharmaceuticals Res Ltd Virale zubereitungen, vektoren, immunogene und impfstoffe
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
ZA966287B (en) * 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
CA2234060A1 (fr) 1995-10-06 1997-04-10 Arch Development Corporation Procedes et compositions de stimulation virale d'elimination de cellules
EP1314430A1 (fr) * 1996-01-25 2003-05-28 The University Court Of The University Of Glasgow Traitement de cancer non neuronal à l'aide d'un mutant de hsv
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
JPH1087503A (ja) * 1996-09-06 1998-04-07 Nippon Chem Res Kk 神経系腫瘍細胞のアポトーシス剤
GB9704046D0 (en) * 1997-02-27 1997-04-16 Univ Leeds Arrestable therapeutic
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
CA2284611A1 (fr) * 1997-03-27 1998-10-01 Richard B. Pyles Virus simplex de l'herpes apte a la replication
US6218103B1 (en) * 1997-04-16 2001-04-17 Arch Development Corporation Herpes simplex virus US3 and ICP4 as inhibitors of apoptosis
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
AU9603898A (en) 1997-10-09 1999-05-03 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US20040151697A1 (en) * 1998-01-08 2004-08-05 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6277621B1 (en) 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
EP1061806A4 (fr) * 1998-03-12 2001-09-12 Univ Pennsylvania Cellules productrices pour virus aptes a la replication utilisees dans le traitement de la malignite
EP1073442A1 (fr) 1998-04-30 2001-02-07 The General Hospital Corporation Therapie combinee des tumeurs a base de genes et de virus
US20020115213A1 (en) * 1998-08-14 2002-08-22 Northeastern Ohio Universities Of Medicine Engraftable neural progenitor & stem cells for brain tumor therapy
US7186409B2 (en) * 1998-08-14 2007-03-06 The Children's Medical Center Corporation Neural stem cells and use thereof for brain tumor therapy
DK1115290T3 (da) * 1998-10-01 2009-06-22 Univ Southern California Retroviralt gentilförselssystem og fremgangsmåder til anvendelse heraf
EP1141338A4 (fr) * 1998-12-31 2002-09-25 Arch Dev Corp Virus de l'herpes simplex recombinant utile dans le traitement des maladies neoplasiques
AU772471B2 (en) * 1999-02-05 2004-04-29 Arch Development Corporation Treatment of tumors with genetically engineered herpes virus
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤
US6774119B1 (en) 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
ES2233349T3 (es) * 1999-08-31 2005-06-16 The General Hospital Corporation Reordenacion por promotores especificos para una celula y/o especificos para un tumor de la expresion del gen gamma 34,5 herpetico.
US6897057B1 (en) * 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
CA2720361A1 (fr) 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Virus pour le traitement des troubles de la proliferation cellulaire
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
DE60107203T3 (de) * 2000-01-21 2009-07-23 Biovex Ltd. Herpes-virusstämme für die gentherapie
AR028040A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
WO2001091789A2 (fr) * 2000-06-01 2001-12-06 Sloan-Kettering Institute For Cancer Research Utilisation de virus herpetiques mutants et d'agents anticancereux dans le traitement du cancer
JP4004952B2 (ja) 2000-11-28 2007-11-07 ザ ユニヴァーシティ オヴ シカゴ 心血管疾患治療のための遺伝的に操作されたヘルペスウイルス
WO2002076216A1 (fr) 2001-03-27 2002-10-03 Medigene, Inc. Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
US20030099616A1 (en) * 2001-07-25 2003-05-29 Irving John M. Dual specificity tumor killing vectors driven by the telomerase promoter
AU2002319961A1 (en) * 2001-07-27 2003-02-17 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
ES2208051B1 (es) * 2002-01-24 2005-08-16 Consejo Sup. Investig. Cientificas Secuencia de acido nucleico que comprende la señal de encapsidacion del rna de un coronavirus del grupo 1 y sus aplicaciones.
AU2003216502B2 (en) * 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
AU2003258060B2 (en) * 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
WO2003083105A1 (fr) * 2002-03-28 2003-10-09 Medicalseed Co., Ltd. Traitement et prevention de l'angiostenose
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
JP2005073653A (ja) * 2003-09-02 2005-03-24 Keio Gijuku ヒトグリオーマ治療に有用な変異ｈｓｖベクター
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2007005876A2 (fr) * 2005-07-01 2007-01-11 The Uab Research Foundation Herpes-virus chimeriques et leurs utilisations
EP2144632B1 (fr) * 2007-05-09 2016-11-16 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Virus herpes simplex de type 1 synthétiques pour le traitement de cancers
US8765444B2 (en) * 2009-07-15 2014-07-01 The Board Of Trustees Of The University Of Illinois Compositions and methods using herpes simplex virus
GB201101167D0 (en) * 2011-01-22 2011-03-09 Renishaw Plc Convection enhanced delivery apparatus and method
CN104884627A (zh) 2012-10-25 2015-09-02 托卡根公司 具有小型启动子盒的逆转录病毒载体
IL308119A (en) 2014-12-18 2023-12-01 Amgen Inc Stable frozen formulation for herpes simplex virus
AU2018235944B2 (en) 2017-03-15 2024-01-04 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
CN118126157A (zh) 2017-08-03 2024-06-04 美国安进公司 白介素-21突变蛋白和治疗方法
EP3664844A1 (fr) 2017-08-07 2020-06-17 Amgen Inc. Traitement du cancer du sein triple négatif ou du cancer colorectal comportant des métastases hépatiques par un anticorps anti-pd-l1 et un virus oncolytique
EP3833765A1 (fr) 2017-08-09 2021-06-16 The Ohio State Innovation Foundation Virus oncolytique portant une e-cadhérine et ses utilisations
EP4141005B1 (fr) 2017-09-08 2024-04-03 Amgen Inc. Inhibiteurs de kras g12c et leurs procédés d'utilisation
US11542524B2 (en) 2017-11-29 2023-01-03 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
JP2022516077A (ja) 2018-12-27 2022-02-24 アムジェン インコーポレイテッド 凍結乾燥ウイルス製剤
EP3935182A1 (fr) 2019-03-05 2022-01-12 Amgen Inc. Utilisation de virus oncolytiques pour le traitement du cancer
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3122669A1 (de) * 1980-06-12 1982-02-11 Asta-Werke Ag, Chemische Fabrik, 4800 Bielefeld "verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2"
NL9001828A (nl) * 1990-08-15 1992-03-02 Centraal Diergeneeskundig Inst Werkwijze voor het wijzigen van het cel-, weefsel- of gastheertropisme van een microoerganisme; aldus verkregen gerecombineerd microorganisme en toepassing daarvan in de geneeskunde en diergeneeskunde.
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5728379A (en) * 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication

Also Published As

Publication number Publication date
ATE409751T1 (de) 2008-10-15
JP3726841B2 (ja) 2005-12-14
WO1996000007A1 (fr) 1996-01-04
CA2193491A1 (fr) 1996-01-04
DE69535851D1 (de) 2008-11-13
DE69535584D1 (de) 2007-10-04
DE69535584T2 (de) 2008-05-15
JPH10501990A (ja) 1998-02-24
EP1428887A1 (fr) 2004-06-16
ATE371036T1 (de) 2007-09-15
US5585096A (en) 1996-12-17
CA2193491C (fr) 2010-04-06
EP0766512A4 (fr) 1999-04-14
EP1428887B1 (fr) 2007-08-22
AU3988897A (en) 1998-01-08
AU679644B2 (en) 1997-07-03
EP0766512B1 (fr) 2008-10-01
AU2906095A (en) 1996-01-19
EP0766512A1 (fr) 1997-04-09

Similar Documents

Publication Publication Date Title
DK0766512T3 (da) Replikationskompetent herpes simplex-virus formidler destruktion af neoplastiske celler
ATE342724T1 (de) Verwendung von herpes-vektoren zur tumortherapie
KR950010236U (ko) 리드핀의 소켓
EP0901780A4 (fr)
ITTV930002A1 (it) Struttura di pattino perfezionato
HK51995A (en) Antimigraine alkxypyrimidine derivatives.
DE69133022T2 (de) Viral verursachte Zerstörung von Neoplastzellen
GB9415320D0 (en) Cancer treatment
DK0625195T3 (da) Behandling af centralnervesystemet med genetisk modificerede celler
ZA941426B (en) Recombinant viruses and their use in gene therapy
ATE55888T1 (de) Kuenstliche hueftgelenkspfanne.
AU558175B2 (en) Sunglasses with an adjustable nose piece
FI875072A (fi) Ryggsaeck.
MA23057A1 (fr) Article absorbant ayant un moyen de fixation adhesif auto-degageable.
USD274094S (en) Tibial positioning/fixation jig for the implanation of a prosthetic knee
MY115301A (en) Absorbent article having a releasable adhesive patch
USD274264S (en) Inflatable splint
IT8648499A0 (it) Dispositivo per fissare in maniera svinzolabile l'accoppiamento trapezzi formati cilindrici,concavi e convessi
ITBZ910020A1 (it) Procedimento per la realizzazione di un accumulatore termico e accumulatore termico per l'attuazione del procedimento.
MX7221E (es) Procedimiento para la preparacion de derivados de los acidos 2 o 4 tiazolidincarboxilicos 3-acil sustituidos
ES8601155A1 (es) Procedimiento para la obtencion de 2-(n-(2-hidroxietil)-carbamoil)-3-metil-quinoxalin-1, 4-n-dioxido estabilizado
ES2061722T3 (es) Derivados de fenantridina, procedimiento para su obtencion y agentes para la realizacion del procedimiento.
IT1302979B1 (it) Trave per un dirigibile
SE8403395D0 (sv) Skap, forsett med veggar av stalplat e d
IT8234029V0 (it) Rete da letto ortopedica, a una odue piazze, ad elasticita'bilanciata con inserimento di elementi trasversali flessibili e compensazione della trazione sul telaio portante.